Creating new peptides to block growth hormone activity
Developing helical peptide antagonists of the growth hormone receptor
This study is looking at new treatments that use special peptides to help block the effects of growth hormone, which can cause health problems like acromegaly and issues related to aging, with the hope of promoting healthier aging and lowering cancer risks.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio University Athens NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10648820 on NIH RePORTER |
What this research studies
This research focuses on developing helical peptide antagonists that can inhibit the action of growth hormone (GH), which is linked to various health issues, including acromegaly and age-related diseases. By designing specific peptides that mimic parts of the growth hormone receptor, the researchers aim to create a treatment that could reduce the negative effects of excessive GH secretion. The approach involves testing these peptides in laboratory settings to evaluate their effectiveness in blocking GH signaling, which may lead to healthier aging and reduced risk of certain cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acromegaly or related disorders characterized by inappropriate growth hormone secretion.
Not a fit: Patients who do not have conditions related to growth hormone dysregulation are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from conditions related to excessive growth hormone secretion, potentially improving their quality of life.
How similar studies have performed: Previous studies have shown promise in using peptide-based therapies to modulate hormone activity, suggesting that this approach could be effective.
Where this research is happening
Athens, United States
- Ohio University Athens — Athens, United States (Active)
Researchers
- Principal investigator: Holub, Justin Matthew — Ohio University Athens
- Study coordinator: Holub, Justin Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.